Search

Thanh Nhan P. Nguyen

Examiner (ID: 7604, Phone: (571)272-1673 , Office: P/2871 )

Most Active Art Unit
2871
Art Unit(s)
2871
Total Applications
1028
Issued Applications
854
Pending Applications
3
Abandoned Applications
171

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16870115 [patent_doc_number] => 20210163582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => ANTIBODIES THAT BIND TO PATHOLOGICAL TAU SPECIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/170446 [patent_app_country] => US [patent_app_date] => 2021-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170446 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/170446
Antibodies that bind to pathological Tau species and uses thereof Feb 7, 2021 Issued
Array ( [id] => 16238605 [patent_doc_number] => 20200255839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => METHOD FOR TREATING A DEGENERATIVE NEUROLOGICAL DISORDERS COMPRISING ADMINISTERING ASM INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/863942 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863942 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/863942
Method for treating a neurological disorder comprising administering ASM inhibitors Apr 29, 2020 Issued
Array ( [id] => 17451854 [patent_doc_number] => 11266691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Methods and materials for producing T cells [patent_app_type] => utility [patent_app_number] => 16/851926 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 4031 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851926 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/851926
Methods and materials for producing T cells Apr 16, 2020 Issued
Array ( [id] => 17392495 [patent_doc_number] => 11241483 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Methods of treating mild brain injury [patent_app_type] => utility [patent_app_number] => 16/844934 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 22557 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844934 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/844934
Methods of treating mild brain injury Apr 8, 2020 Issued
Array ( [id] => 16328415 [patent_doc_number] => 20200299381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ROR1 Antibody Compositions and Related Methods [patent_app_type] => utility [patent_app_number] => 16/805102 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805102 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/805102
ROR1 antibody compositions and related methods Feb 27, 2020 Issued
Array ( [id] => 16375102 [patent_doc_number] => 20200323944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => Compositions and Methods for Treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) and Other Neurodegenerative Disorders Associated with Aberrant Amyloid Deposits [patent_app_type] => utility [patent_app_number] => 16/789923 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789923 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/789923
Compositions and methods for treatment of hereditary cystatin C amyloid angiopathy (HCCAA) and other neurodegenerative disorder associated with aberrant amyloid deposits Feb 12, 2020 Issued
Array ( [id] => 17251158 [patent_doc_number] => 11186630 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Anti-transthyretin human antibody [patent_app_type] => utility [patent_app_number] => 16/783560 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 16065 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783560 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/783560
Anti-transthyretin human antibody Feb 5, 2020 Issued
Array ( [id] => 16326835 [patent_doc_number] => 20200297800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION [patent_app_type] => utility [patent_app_number] => 16/782908 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782908 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/782908
USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION Feb 4, 2020 Abandoned
Array ( [id] => 16206532 [patent_doc_number] => 20200239522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => Optimized Peptides for Targeting Human Nerves and Their Use in Image Guided Surgery, Diagnostics and Therapeutic Delivery [patent_app_type] => utility [patent_app_number] => 16/780782 [patent_app_country] => US [patent_app_date] => 2020-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16780782 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/780782
Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic delivery Feb 2, 2020 Issued
Array ( [id] => 15556853 [patent_doc_number] => 20200062838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/569101 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16569101 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/569101
METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS Sep 11, 2019 Abandoned
Array ( [id] => 15267521 [patent_doc_number] => 20190382494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/553670 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553670 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/553670
COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES Aug 27, 2019 Abandoned
Array ( [id] => 17938429 [patent_doc_number] => 11472870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Pharmaceutical composition for safe and effective treatment of knee and/or hip pain [patent_app_type] => utility [patent_app_number] => 16/536706 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 52 [patent_no_of_words] => 24097 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16536706 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/536706
Pharmaceutical composition for safe and effective treatment of knee and/or hip pain Aug 8, 2019 Issued
Array ( [id] => 16816802 [patent_doc_number] => 11001608 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Arid5a peptide inhibitors [patent_app_type] => utility [patent_app_number] => 16/508601 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 3018 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508601 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/508601
Arid5a peptide inhibitors Jul 10, 2019 Issued
Array ( [id] => 15556851 [patent_doc_number] => 20200062837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => ANTI-NGF COMPOSITIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/504602 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16504602 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/504602
ANTI-NGF COMPOSITIONS AND USE THEREOF Jul 7, 2019 Abandoned
Array ( [id] => 15408067 [patent_doc_number] => 20200024355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/505288 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16505288 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/505288
USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT Jul 7, 2019 Abandoned
Array ( [id] => 15882865 [patent_doc_number] => 10647764 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Agents, uses and methods for the treatment of synucleinopathy [patent_app_type] => utility [patent_app_number] => 16/443225 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 45 [patent_no_of_words] => 31690 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443225 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/443225
Agents, uses and methods for the treatment of synucleinopathy Jun 16, 2019 Issued
Array ( [id] => 15209817 [patent_doc_number] => 20190367595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY [patent_app_type] => utility [patent_app_number] => 16/443249 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443249 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/443249
Agents, uses and methods for the treatment of synucleinopathy Jun 16, 2019 Issued
Array ( [id] => 15882863 [patent_doc_number] => 10647763 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Agents, uses and methods for the treatment of synucleinopathy [patent_app_type] => utility [patent_app_number] => 16/443187 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 45 [patent_no_of_words] => 31703 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443187 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/443187
Agents, uses and methods for the treatment of synucleinopathy Jun 16, 2019 Issued
Array ( [id] => 14896993 [patent_doc_number] => 20190292262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 16/439396 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439396 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/439396
Low dose immune checkpoint blockade in metastatic cancer Jun 11, 2019 Issued
Array ( [id] => 15898485 [patent_doc_number] => 20200148761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE [patent_app_type] => utility [patent_app_number] => 16/437776 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437776 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/437776
PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE Jun 10, 2019 Abandoned
Menu